Navigation Links
Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder
Date:6/8/2009

Research Published by Scripps Associate Professor Xiang-Lei Yang Further Validates aTyr Pharma's Discovery Engine for Proprietary Drugs

SAN DIEGO, June 8 /PRNewswire/ -- The June 1st, 2009 edition of The Scripps Research Institute (TSRI) News & Views highlights newly published research from the laboratory of Associate Professor Xiang-Lei Yang, a scientific co-founder of aTyr Pharma. Professor Yang's latest study (Chemistry & Biology, vol. 16, pp. 531-539) builds on her previous revolutionary research with an essential enzyme of protein synthesis, tyrosyl tRNA synthetase. Synthetases are fundamental components of protein synthesis machinery in all organisms, but human synthetases have hidden secrets: unrelated cell signaling activities that play key roles in balancing the complex human system. By proving that cytokine-disrupting mutations in the tyrosyl tRNA synthetase do not disturb the activity required for protein synthesis, Professor Yang's research demonstrates that human synthetases have evolved mechanisms for switching on new cell signaling activities that are normally masked in the synthetase enzymes. The novel cell signaling activities associated with the tyrosyl tRNA synthetase extends to the whole family of synthetases and is the basis of aTyr Pharma's discovery engine for developing an entirely new class of protein drugs.

According to Jeff Watkins, CEO of aTyr Pharma, "By separating specific residues in the human tyrosyl tRNA synthetase required for novel cytokine activities from those involved in the protein synthesis activities, Professor Yang has proven that these naturally occurring activities hidden in the synthetases have a role in normal human physiology. Identification of these novel cell signaling proteins that can be used to restore homeostasis in patients with inflammatory, cardiovascular and metabolic diseases is the discovery engine for aTyr Pharma's product development program and we are pleased TSRI has highlighted the significance of Professor Yang's work in this field."

Professor Paul Schimmel, a co-founder of aTyr Pharma and Professor Yang's colleague at TSRI, adds: "While the roles of aminoacyl tRNA synthetases in protein synthesis have been well studied for decades, the cell signaling activities for the naturally occurring proteins embedded in the synthetases represent a new class of proteins with therapeutic potential. The work done by Professor Yang and her group has contributed immensely to our understanding of how the genes encoding these ancient enzymes have evolved to include broader roles in regulating the systems biology of humans." An expert on tRNA synthetases, Paul Schimmel has also been the co-founder of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, Repligen, Momenta Pharmaceuticals and Cubist Pharmaceuticals.


'/>"/>
SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
3. Instrumentation Laboratory Ships 1000th GEM Premier 4000 Analyzer to Scripps Health
4. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
5. Researchers solve bloodcurdling mystery
6. Akaza Research to Present and Exhibit at Upcoming DIA Annual Meeting
7. Sigma-Aldrich Honored With CIO 100 Award for Innovative Web Research Tool, Your Favorite Gene powered by Ingenuity
8. Kornberg Associates Architects Selected to Design Research Areas of Malaysia Genome Institute
9. First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes
10. Secret of sandcastle construction could help revive ancient building technique, researchers say
11. Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , April 27, 2017  Kinexum, a distinguished resource ... today announces the appointment of Thomas C. Seoh ... ("Zan") Fleming, M.D., Kinexum founder, who becomes Executive Chairman ... to Kinexum clients. Thomas Seoh ... the Kinexum mission and lead the firm,s remarkable team ...
(Date:4/26/2017)... Alto, CA, USA (PRWEB) , ... April 26, ... ... popular seminar on FDA’s GMP expectations for phase I clinical trials comes to ... attended by various biotechnology and pharma professionals representing FDA regulated organizations such as ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... in EMEA and North America this May on the ... 16-18 , Donald H. Taylor, Chairman of the Learning and Performance Institute will ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the Stago EdVantage Virtual ... testing for DIC in order to illuminate this clinical problem for people unfamiliar with ... patients resulting in a high degree of morbidity and mortality. DIC is a confusing ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):